MC 838: RN given refers to Ca[2:1]salt(R-(R*,S))-isomer; structure given in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
| ID Source | ID |
|---|---|
| PubMed CID | 6917881 |
| SCHEMBL ID | 5604459 |
| MeSH ID | M0140601 |
| Synonym |
|---|
| mc-838 |
| moveltipril calcium |
| lowpress |
| altiopril calcium |
| calcium (-)-n-(((s)-3-(n-cyclohexylcarbonyl-d-alanyl)thio)-2-methylpropionyl)-l-prolinate |
| mc 838 |
| lowpres |
| l-proline, 1-(3-((2-((cyclohexylcarbonyl)amino)-1-oxopropyl)thio)-2-methyl-1-oxopropyl)-, calcium salt (2:1), (r-(r*,s*))- |
| moveltipril calcium salt |
| 85921-53-5 |
| sb44s25he5 , |
| unii-sb44s25he5 |
| moveltipril calcium [jan] |
| moveltipril calcium salt [mi] |
| l-proline, n-(cyclohexylcarbonyl)-d-alanyl-(2s)-3-mercapto-2-methylpropanoyl-, calcium salt (2:1) |
| SCHEMBL5604459 |
| calcium(s)-1-((s)-3-(((r)-2-(cyclohexanecarboxamido)propanoyl)thio)-2-methylpropanoyl)pyrrolidine-2-carboxylate |
| Q27289124 |
| calcium;(2s)-1-[(2s)-3-[(2r)-2-(cyclohexanecarbonylamino)propanoyl]sulfanyl-2-methylpropanoyl]pyrrolidine-2-carboxylate |
| Excerpt | Relevance | Reference |
|---|---|---|
| ", captopril appeared in approximately 40% of MC-838 in serum, indicating that the amount of serum captopril during the equimolar concentration treatment with MC-838 corresponds to half of serum captopril after the dosing of captopril." | ( Tissue angiotensin-converting enzyme blockade by MC-838 (altiopril calcium) infused intravenously to miniature pigs: comparison with captopril. Akima, M; Hinohara, Y; Ichihara, T; Imagawa, J; Koga, T; Sakai, K; Shiraki, Y; Tohira, Y, ) | 0.13 |
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 7 (100.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| This Compound (18.14) All Compounds (24.57) |
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||